Vera Therapeutics
VERA
50 hedge funds and large institutions have $469M invested in Vera Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
35% more funds holding
Funds holding: 37 → 50 (+13)
25% more capital invested
Capital invested by funds: $375M → $469M (+$94M)
6.64% more ownership
Funds ownership: 67.02% → 73.66% (+6.6%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$42.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.7M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$14.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.67M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$8.87M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$2.06M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$576K |
| 4 |
CMU
Carnegie Mellon University
Pittsburgh,
Pennsylvania
|
-$346K |
| 5 |
Jane Street
New York
|
-$221K |
VERA Hedge Fund Activity: Q1 2022 in Review
50 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q1 2022, worth a combined $469M — up 25% from $375M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new VERA positions and 2 closed out — a net gain of 13 holders — while 23 added to existing stakes and 8 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $42.3M. The largest seller was Alphabet Inc, cutting an estimated $8.87M.
- 50 institutional investors held Vera Therapeutics (VERA) as of Q1 2022, up from 37 in Q4 2021.
- Funds reported $469M of Vera Therapeutics stock for Q1 2022, up 25% quarter-over-quarter.
- 15 funds opened new Vera Therapeutics positions in Q1 2022 and 2 closed out, a net change of +13 holders.
- The largest Vera Therapeutics buyer in Q1 2022 was RA Capital Management, an estimated $42.3M added.
- The largest Vera Therapeutics seller in Q1 2022 was Alphabet Inc, an estimated $8.87M sold.
Based on aggregated 13F filings for Q1 2022.